On 31th, Philosys Healthcare announced that it has secured Asia exclusive rights of next-generation bone graft substitute technology developed by Molecular Matrix, Inc. (MMI).

Philosys Healthcare obtained the sales rights exclusive on Asian markets based on the MOU signed with Molecular Matrix in August last year. The company hereby plans to enter 3D tissue engineering in earnest after receiving approval by submitting U.S. clinical trials data to major Asian countries such as Japan and China.

The signing ceremony between Philosys Healthcare and Molecular Matrix (Photo by: Philosys Healthcare)

Molecular Matrix is a bio venture company that started as a startup in UC Davis. After more than 10 years of research and development, the company developed a scaffold structure for organoids (in vitro produced bone replicas). Unlike conventional protein-based scaffolds, the scaffold structure developed by Molecular Matrix is featured by non-toxic, biodegradable and hard enough to withstand heat and pressure due to the use of carbohydrates. The product is based on a patent technology of hyper-crosslinked carbohydrate polymer(HCCP).

The first product that applied Molecular Matrix's HCCP technology, Osteo-PTM BGS (Bone Graft Substitute) is elastic, making it easy to use during surgery and suture with surrounding tissue. Another advantage is that real-time monitoring of bone tissue regeneration is possible.

The medical industry is paying attention to this collaboration. MD Greg Anderson, president of the Society for Minimally Invasive Spinal Surgery, and MD Kee Kim, the chief of spinal neurosurgery at UC Davis, participated in the clinical trials. And they are preparing the paper based on the data.

When used alone, Osteo-PTM has been demonstrated to be equivalent to autologous bone grafts that cause osteoblasts to migrate to the patient's damaged bone defects and heal the bones themselves. In December 2017, it obtained the U.S. Food and Drug Administration (FDA) license and has been selling to hospitals across the U.S. since early last year.


Copyright © acrofan All Right Reserved